ROCKLAND, Mass. and NEW YORK, May 14, 2019 /PRNewswire/ -- BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatmen
Gilead Sciences announced that it will provide free Truvada as PrEP for 200,000 people through 2030. Activists say Gilead is moving to protect Truvada revenue.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifite
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL® (tafamidis meglumine) and VYNDAMAX
AveXis, a Novartis company, announced interim data from ongoing trials of the investigational product Zolgensma or onasemnogene abeparvovec-xioi; AVXS-101 that showed positive results across a broad spectrum of patients with spinal muscular atrophy or SMA.
ViiV HC submits New Drug Application to US FDA for first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
(RTTNews) - The therapeutic armamentarium for plaque psoriasis patients is fairly well-stocked, and now there is one more addition to it.The FDA ha
MARLBOROUGH, Mass., April 23, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Dru
NEW YORK and HERTFORDSHIRE, England and PITTSBURGH, April 18, 2019 /PRNewswire/ -- Non-profit drug developer, TB Alliance, and pharmaceutical company
Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop